Regeneron Pharmaceuticals Inc (REGN)

Return on equity (ROE)

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net income	US$ in thousands	3,953,600	4,338,400	8,075,300	3,513,200	2,115,800
Total stockholders’ equity	US$ in thousands	25,973,100	22,664,000	18,768,800	11,025,300	11,089,700
ROE		15.22%	19.14%	43.03%	31.86%	19.08%

December 31, 2023 calculation

ROE = Net income ÷ Total stockholders’ equity
= $3,953,600K ÷ $25,973,100K
= 15.22%

Regeneron Pharmaceuticals, Inc.'s return on equity (ROE) has exhibited fluctuations over the past five years. In 2023, the ROE stands at 15.22%, indicating a decrease compared to the previous year's 19.14%. This downward trend suggests that the company may be experiencing challenges in generating profits from the shareholders' equity during the most recent fiscal year.

The significant drop in ROE from 2021 to 2022, where ROE decreased from 43.03% to 31.86%, indicates a substantial decrease in the company's efficiency in utilizing equity to generate profits. However, the sharp increase in ROE from 2019 to 2021, reaching 43.03% in 2021, indicates a period of strong performance where the company efficiently leveraged its equity to generate higher returns.

Overall, Regeneron Pharmaceuticals, Inc.'s ROE has shown variability over the past five years, reflecting fluctuations in the company's profitability and efficiency in utilizing shareholder equity. Investors and stakeholders may need to consider the reasons behind these fluctuations to assess the company's financial health and sustainability in the long term.